Introduction
Release of hematopoietic progenitor cells (HPCs) to the circulation is the outcome of signals provided by cytokines, chemokines, adhesion molecules, proteolytic enzymes, and their inhibitors, resulting in prevention of HPC retention in the BM and induction of egress and recruitment of immature cells (1) . Clinical mobilization of immature human CD34 + cells to the peripheral blood (PB) mimics enhancement of their physiological egress from the BM in response to stress signals during injury and inflammation and is achieved by chemotherapy and/or repeated G-CSF stimulations. Understanding the molecular pathways governing egress of progenitor cells from the BM to the circulation has major relevance for clinical stem cell mobilization and transplantation protocols.
Accumulating data indicate that G-CSF-induced leukocyte proliferation and recruitment from the BM are mediated by secreted MMP-9 as well as several serine proteases, including elastase and cathepsins G and K (1) (2) (3) (4) . For instance, cell membrane peptidase CD26/DPPIV has also been implicated in G-CSF mobilization of murine progenitor cells (5) . In the course of mobilization, these proteolytic enzymes cleave cell membrane-and ECM-anchored molecules such as VCAM-1, c-kit, CXCR4, and SDF-1, affecting cell adhesion and chemotaxis, though mice that lack some of these proteases display unimpaired responses to G-CSF (reviewed in ref. 6 ). These findings indicate that distinct, nonoverlapping processes and multiple levels of regulation are involved in HPC egress and mobilization from the BM.
MMPs are members of the diverse family of proteases, which mediate changes in tissue structure and cellular behavior both in normal and disease conditions, and are key regulators of cell motility (7) . Function of membrane type 1-MMP (MT1-MMP) is essential for angiogenesis, wound healing, and connective tissue remodeling (8) , tumor growth and metastasis (9) (10) (11) , and monocyte migration in vitro (12) . MT1-MMP promotes cell invasion and motility by pericellular ECM degradation as well as shedding of cell adhesion molecules, such as CD44 (8) . We have formerly reported that adhesion and homing of immature human CD34 + cells to the BM of immunodeficient mice is CD44 dependent (13) . Of interest, clinical data reveal that membranal levels of several adhesion receptors, including CD44, are diminished on human G-CSF-mobilized HPCs relative to BM-resident CD34 + HPCs (14, 15) .
Among numerous regulatory mechanisms, MT1-MMP activity is tightly controlled under normal and pathophysiological conditions by endogenous inhibitors (16) . Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a transformation suppressor protein whose expression is inversely associated with invasion of various tumor cell types (17) . RECK is suggested to act as a membrane-anchored inhibitor of MT1-MMP, MMP-2, and MMP-9 expression and activation (18) , though the mechanism is not fully resolved. The role of MT1-MMP and RECK in the regulation of HPC trafficking in vivo, stress-induced recruitment, and clinical mobilization was not evaluated. In the present study, we found that BM retention and egress of human CD34 + HPCs and murine progenitors are dependent on MT1-MMP and RECK functional levels and MT1-MMP-mediated CD44 membranal cleavage, implicating MT1-MMP activity in G-CSF-induced mobilization.
Results

MT1-MMP expression is positively correlated with human CD34 + HPC egress and G-CSF mobilization.
First we examined MT1-MMP and RECK expression on human HPCs. We identified membranal MT1-MMP expression on immature human CD34 + progenitors by flow cytometry ( Figure 1A ). We detected higher MT1-MMP surface protein amounts on CD34 + cells enriched from steady-state PB of healthy human donors (termed "steady state"), as compared with their BM counterparts. Membranal MT1-MMP expression was even more prominent on CD34 + cells found in mobilized PB (MPB) of G-CSF-treated healthy donors for clinical BM transplantation. Further, BM CD34 + HPCs from untreated healthy donors displayed RECK expression ( Figure 1A ). Of note, BM CD34 + cells expressed both MT1-MMP and RECK ( Figure 1A , right), whereas RECK labeling was not detected on CD34 + cells obtained from the PB of steady-state and G-CSF-treated healthy donors ( Figure 1A) . Only ex vivo G-CSF treatment elevated MT1-MMP levels on isolated CD34 + cells enriched from the BM of untreated healthy donors, while other cytokines tested had no such effect ( Figure 1B ). These data suggest that steady-state egress of human HPCs and, to a higher extent, G-CSF-induced mobilization, are accompanied by an increase in MT1-MMP and a parallel reduction in RECK expression. To evaluate the clinical relevance of the dynamic changes in MT1-MMP expression during mobilization, we examined correlations between MT1-MMP cell surface levels and the numbers of immature CD34 + cells mobilized by G-CSF. RECK expression on CD34 + cells enriched from PB of G-CSF-treated donors was relatively low ( Figure 1A ) and was therefore not examined. Analysis of samples obtained from the MPB of 21 consecutive G-CSF-treated healthy donors harvested for allogeneic transplantations revealed a significant correlation between MT1-MMP expression levels and the numbers of mobilized CD34 + cells ( Figure 1C ; P < 0.01). We also found that MT1-MMP expression was positively correlated with CD34 + cell mobilization to the PB of 29 consecutive patients with lymphoid malignancies treated with G-CSF in the recovery phase of chemotherapy ( Figure 1D ; P < 0.001).
Opposite MT1-MMP and RECK expression upon steady-state release and G-CSF-induced mobilization in chimeric NOD/SCID mice. Next we studied changes in human MT1-MMP and RECK levels in the functional in vivo model of immunodeficient NOD/SCID chimeric mice (19, 20) . Inverse expression of MT1-MMP and RECK mRNA by G-CSF treatment was detected in human cells repopulating the BM of chimeric mice (Figure 2A ). These findings were also verified in a murine model of G-CSF-induced mobilization in Balb/c mice (see Figure 3D ) and further confirmed by immunolabeling of BM sections from highly engrafted chimeric mice ( Figure 2B ). G-CSF-induced changes in MT1-MMP and RECK levels resulted in an increase in MT1-MMP activity in the BM cells of chimeric mice ( Figure 2C ), indicative of functional MT1-MMP involvement in the mobilization process. We then determined that in control sham-treated chimeric mice, MT1-MMP surface expression on human CD34 + HPCs and total CD45 + hematopoietic cells was significantly higher in PB (P < 0.05) as compared with human cells repopulating the BM of the same mice ( Figure  2D , BM versus PB). Following G-CSF treatment, we observed a 3-to 4-fold increase in MT1-MMP surface labeling on total human CD45 + leukocytes and, specifically, immature CD34 + cells in the BM and PB ( Figure 2D) . In parallel, G-CSF treatment decreased membranal RECK expression by 30%-40% on both immature human CD34 + and maturing CD45 + cells in the BM and PB of chimeric mice ( Figure 2E ). Importantly, the opposite changes by G-CSF in MT1-MMP and RECK levels were also detected in the rare population of primitive BM CD34 + /CD38 -/low human HPCs, which contained repopulating stem cells (Figure 2, D and E) . Taken together, our data show that MT1-MMP and RECK expression are inversely regulated upon G-CSF mobilization, implying a role for these dynamic changes in HPC egress.
G-CSF-induced changes in MT1-MMP and RECK expression are dependent on PI3K/Akt activity. We further found that the effect of ex vivo G-CSF treatment on MT1-MMP and RECK membranal expression on human CD34 + cells obtained from the BM of NOD/SCID chimeric mice was reversed upon PI3K inhibition ( Figure 3A ). In accordance, we detected increased phosphorylation of Akt, a substrate of activated PI3K, in the BM of G-CSFtreated chimeric mice ( Figure 3B ), specifically, in human CD45 + leukocytes and immature CD34 + cells ( Figure 3C ). Based on these results, we suggest that MT1-MMP and RECK regulation by G-CSF depends on PI3K/Akt-mediated signaling. Next we found that treatments with the drug rapamycin, an inhibitor of mTOR, which is a downstream effector of PI3K/Akt activation (reviewed in ref. 21) , antagonized the inverse effects of G-CSF on MT1-MMP and RECK expression in Balb/c mice ( Figure 3D ). These data indicate that PI3K/Akt signaling is involved in the regulation of functional MT1-MMP levels. Accordingly, we observed a decrease in G-CSF-induced mobilization of immature murine CFU cells in Balb/c mice co-injected with rapamycin ( Figure 3E ), indicating that interference with G-CSF-induced PI3K signaling and MT1-MMP activation antagonizes HPC mobilization.
MT1-MMP and RECK affect migration, homing, and engraftment of human and murine HPCs. A major hallmark of hematopoietic stem cells is their motility, which enables bidirectional trafficking across the endothelium and ECM barriers during BM egress and homing processes (22) . The chemokine SDF-1 is the major attractant implicated in chemotaxis in vitro of murine (23) and in vivo repopulation of NOD/SCID mice by human stem and progenitor cells (24) . SDF-1-induced motility of MPB CD34 + cells in vitro correlates with hematopoietic recovery after clinical autologous transplantation (25) . To study MT1-MMP involvement in SDF-1-induced chemotaxis, we administered human-specific anti-MT1-MMP Abs, which inhibit its enzymatic function (26) . We found that treatment with anti-MT1-MMP Abs, but not with control IgG, reduced the in vitro chemotactic response to SDF-1 via Matrigel of enriched human G-CSF-mobilized PB (MPB) CD34 + cells ( Figure 4A ). TIMP-2, which hinders the enzymatic activity of MT1-MMP, MMP-2, as well as several other MMPs, had a similar inhibitory effect on SDF-1-induced motility of human G-CSF-mobilized HPCs ( Figure 4A , MPB CD34 + ). In accordance, a 30%-50% reduction in MT1-MMP expression on enriched MPB tive transfer into congenic host. We detected impaired in vitro trans-Matrigel migration of MT1-MMP-deficient cells compared with WT counterparts ( Figure 4D ).
We further found that pretreatment with MT1-MMP neutralizing Abs interfered with homing of human G-CSF-MPB CD34 + cells to the BM of transplanted NOD/SCID mice compared with cells treated with anti-human VLA-6 Abs ( Figure 5A ). Targeting MT1-MMP expression by siRNA but not control transfections decreased to a similar extent the homing of MPB CD34 + progenitors ( Figure 5B ). BM cells obtained from MT1-MMP KO mice also exhibited reduced homing capacity to the BM of transplanted NOD/SCID mice compared with WT littermates ( Figure 5C ). Finally, we applied a chimeric mouse model, in which BM cells (CD45.2 + ) obtained from either MT1-MMP KO or WT 14-day-old littermates were transplanted into sub-lethally irradiated B6.SJL (CD45.1 + ) recipients. In line with an impaired homing capacity of MT1-MMP-deficient cells into NOD/SCID mice ( Figure 5C ), we found that engraftment levels of repopulating BM CD45.2 + / c-kit + donor-derived progenitors from MT1-MMP KO mice were significantly lower than the levels of CD45.2 + /c-kit + cells obtained from their WT littermates in the BM of the recipient mice ( Figure  5D ; P < 0.01). Collectively, these results indicate a functional role for MT1-MMP in directional motility and in vivo trafficking of human and murine HPCs.
MT1-MMP activity is required for mobilization of human and murine HPCs. To examine further the direct involvement of MT1-MMP in HPC mobilization, we administered function-blocking MT1-MMP Abs during the course of G-CSF treatment of NOD/SCID chimeric mice. MT1-MMP neutralization abrogated the increase in numbers of maturing human PB CD45 + leukocytes, immature CD34 + cells, and importantly, the more primitive CD34 + /CD38 -/low HPCs following G-CSF administrations ( Figure 6A ). Treatments with anti-human VLA-6 Abs as a control did not interfere with G-CSFinduced mobilization ( Figure 6A ). To substantiate these findings, we examined G-CSF-induced mobilization of MT1-MMPdeficient cells. MT1-MMP KO mice die at a very early age due to severe developmental defects (27) and can not sustain G-CSF injections. Therefore, we utilized the chimeric mouse model of sublethally irradiated B6.SJL (CD45.1 + ) mice engrafted with either MT1-MMP-deficient or WT CD45.2 + BM cells. In this system, we observed an inferior G-CSF-induced mobilization of MT1-MMPdeficient CD45.2 + /c-kit + cells compared with the WT counterparts ( Figure 6B ). These results indicate that functional MT1-MMP is important for an optimal HPC mobilization by G-CSF. Next we found that under steady-state conditions, compromising human RECK activity by the injection of neutralizing Abs resulted in a 4-fold increase in the numbers of maturing human CD45 + and immature CD34 + cells in the PB of chimeric NOD/SCID mice compared with control IgG-treated mice ( Figure 6C ). RECK downregulates MMP-2 activation and MMP-9 expression in vivo (18, 28) . Accordingly, in the BM fluids of anti-RECK-injected mice, we have detected increased levels of secreted MMP-2 and MMP-9 (Figure 6D) , indicative of RECK inhibition by the Abs.
MT1-MMP is involved in membranal CD44 cleavage during G-CSFinduced mobilization.
To investigate potential targets of MT1-MMP in progenitor cell mobilization, we examined proteolysis of the CD44 adhesion molecule, as previous studies have implicated shedding of the CD44 extracellular portion by MT1-MMP in malignant cell motility (29) . Following G-CSF-induced mobilization in highly engrafted chimeric mice, we observed reductions of human CD44 labeling in BM sections ( Figure  7A ), on human BM and PB CD45 + cells (data not shown), and specifically, on the immature human CD34 + progenitors, as determined by flow cytometry ( Figure 7B ). Moreover, G-CSF treatment was accompanied by accumulation of CD44 cleavage products expected for MT1-MMP activity (30) in the BM supernatants of G-CSF-treated mice ( Figure 7C ). In chimeric mice co-injected with G-CSF and MT1-MMP-neutralizing Abs, CD44 membranal expression on human CD34 + cells was similar to the levels in control mice ( Figure 7B ). Accordingly, fewer cleavage products of CD44 were detected in the BM fluids of G-CSF and anti-MT1-MMP cotreated mice compared with G-CSF only counterparts ( Figure 7C ). Further, in the absence of G-CSF stimulation, increasing functional MT1-MMP by anti-human RECK Abs injection facilitated CD44 cleavage on BM cells (Figure 7C, αRECK) . To demonstrate a role for MT1-MMP in G-CSFinduced CD44 cleavage, we utilized the human U937 cell line as a model for myeloid cells. Reducing MT1-MMP expression by siRNA attenuated the G-CSF-induced decrease in CD44 protein on the membrane ( Figure 7D ). These results indicate that activation of MT1-MMP directly affects membranal CD44. Further, CD44-mediated adhesion to hyaluronan of human CD34 + cells obtained from the BM of chimeric mice was reduced 5-fold following G-CSF mobilization and was largely restored following coadministration of anti-MT1-MMP Abs to G-CSF-treated mice ( Figure 7E ). MT1-MMP activation by G-CSF or anti-RECK Abs treatment ex vivo was also accompanied by a decrease in CD44-dependent adhesion to hyaluronan of human CD34 + HPCs present in the BM of control chimeric mice ( Figure 7F) . This effect of G-CSF was partially diminished upon MT1-MMP neutralization ( Figure 7F, αMT1-MMP) . We further detected significantly increased frequencies of circulating immature colony forming cells ( Figure 7G ; P < 0.01) and primitive lineage -c-kit + Sca-1 + HPCs ( Figure 7H ) in CD44-deficient (CD44 -/-) mice as compared with WT counterparts (CD44 +/+ ). Based on our findings, we propose that one of the mechanisms by which MT1-MMP and RECK oppositely affect egress of HPCs to the circulation is by regulating CD44 cell-surface levels.
Discussion
In the present study we found that the balance between MT1-MMP and RECK expression is involved in the regulation of homing, retention, egress, and mobilization of immature human CD34 + cells and maturing leukocytes.
We have detected that upon steady-state release and, more significantly, following mobilizing stimuli by G-CSF, MT1-MMP expression and activity were increased on human progenitor cells. We have further established that MT1-MMP expression was positively correlated with G-CSF-induced mobilization of human CD34 + cells in healthy donors for allogeneic transplantation and in mobilized patients with hematological malignancies. These data point to the involvement of MT1-MMP in clinical G-CSF-induced mobilization of human CD34 + HPCs. Analogous mechanisms have been implicated in human and murine HPC mobilization. In accordance, MT1-MMP and RECK expression were similarly affected by G-CSF in BM cells from humans and Balb/c mice. The effect of G-CSF could be both direct and indirect, mediated by cytokine secretion and microenvironmental changes, as previously shown for mobilization of murine progen- itor cells (31) . We detected elevated MT1-MMP levels following G-CSF treatment of isolated BM CD34 + cells from healthy donors. These results point to a cell-autonomous mechanism of MT1-MMP regulation by HPCs, which also takes place in the absence of BM stroma components.
We next demonstrated that inverse expression levels of MT1-MMP and RECK in human and murine progenitor cells were dependent on the PI3K/Akt pathway. Inhibition of the PI3K-mediated signaling by rapamycin treatment antagonized the G-CSFinduced HPC mobilization in Balb/c mice. In support of our results, a substantially greater release of HPCs to the circulation, impaired BM retention (32), and self-renewal (33) were reported in mice with abnormal PI3K activation due to PTEN deficiency. MT1-MMP and RECK are established regulators of endothelial and malignant cell motility (17, 34) . Our data show that optimal SDF-1-induced directional migration via a reconstituted ECM barrier is dependent on MT1-MMP activity. Similarly, MMP-2 and MMP-9 expression and secretion were demonstrated for G-CSFmobilized and steady-state circulating but not BM-residing human CD34 + progenitors, which exhibited inferior spontaneous trans-Matrigel migration in vitro (35) . Our results indicate that in vivo homing of HPCs is dependent on MT1-MMP activity. Notably, comparable results on migration and homing of enriched immature human CD34 + cells were obtained following MT1-MMP targeting by Abs, TIMP-2, and siRNA. These data were further substantiated by the defective homing and engraftment of BM cells from MT1-MMP-deficient mice, demonstrating that functional MT1-MMP is required for efficient HPC trafficking. We have recently reported that catecholaminergic neurotransmitters increase MT1-MMP and MMP-2 expression in vitro on immature human cord blood CD34 + cells, which might contribute to their improved migration and BM engraftment (36) . We then found that blocking MT1-MMP function by Abs interfered with G-CSF-induced mobilization of human HPCs and maturing cells, whereas diminishing RECK activity, potentially increasing levels of functional MT1-MMP, MMP-2, and MMP-9, facilitated human CD34 + release to the circulation. These data were further corroborated by the impaired G-CSFinduced mobilization of BM-residing MT1-MMP-deficient c-kit + cells compared with cells from WT littermates in a chimeric mouse model. RECK mutation is lethal, and KO embryos die in utero (18) . MT1-MMP KO mice die at a very early age and have multiple developmental defects, including impaired growth, angiogenesis, and bone turnover, altering the BM microenvironment (27, 37) . Thus, future experiments with conditional KO mice can contribute to the understanding of cell-autonomous effects of RECK and MT1-MMP in HPC mobilization. Our data also indicate that mobilization is the result of a balance between proteases and their inhibitors. Similarly, it was previously shown that the levels of serpins, endogenous serine protease inhibitors, are decreased in the course of murine mobilization (38) .
We have found that upon G-CSF mobilization, the increase in functional MT1-MMP resulted in CD44 cleavage and reduced CD44-mediated adhesion of BM progenitor cells. We have also observed relatively higher CD44 membranal expression levels on BM c-kit + cells obtained from MT1-MMP KO mice as compared with their WT littermates (data not shown). Moreover, we have detected increased frequencies of circulating HPCs in CD44-deficient mice, indicative of defective interactions with the BM microenvironment in the absence of functional CD44. CD44 is involved in cell-cell and cell-ECM interactions through binding to hyaluronan, which is highly concentrated in the human endosteal region (13) . In addition, hyaluronan expressed on primitive murine HPCs is functionally significant for the homing of HPCs to the endosteum (39) . Another potential ligand for CD44 on normal human HPCs is E-selectin (40) , shown to regulate cell trafficking and BM lodgment. Earlier studies have demonstrated that administration of anti-CD44 Abs causes mobilization of murine HPCs (41) , and combining G-CSF with a blockade of CD44 function improves mobilization efficiencies in mice (42) . Based on these data, we suggest that MT1-MMP facilitates progenitor cell release also by antagonizing adhesion interactions, for example CD44-mediated retention. In support of our approach, reduced adhesion in the BM due to protease-mediated cleavage of the adhesion molecules VLA-4 and VCAM-1 has been implicated in G-CSF-induced mobilization (43, 44) . Despite compensation by other hyaluronan adhesion receptors, such as RHAMM (45), CD44-null mice have reduced blood cellularity, in particular of mature myeloid cells (data not shown), and exhibit hematological impairments (46) . These and our data point on the important role of CD44 in the regulation of HPC homeostasis.
Based on our findings, we propose that retention and egress of human CD34 + cells are regulated cell autonomously by opposite functions of RECK and MT1-MMP (Figure 8 ): G-CSF-induced PI3K activation leads to a decrease in RECK and an increase in MT1-MMP expression, resulting in elevated MT1-MMP activity. RECK inhibition also increases MMP-2 and MMP-9 levels. MT1-MMP-mediated proteolysis of CD44 diminishes HPC adhesion to BM components and facilitates motility, eventually leading to cell egress and improved mobilization. In summary, the data described in the present study highlight the roles of MT1-MMP and RECK in steady-state human HPC retention and provide a previously undefined mechanism for clinical G-CSFinduced mobilization of CD34 + HPCs. Conceivably, clinical Flow cytometry. The number of human cells in the PB and BM of recipient NOD/SCID mice was detected with human-specific anti-CD45-FITC or anti-CD45-APC (both from IQ Corporation), anti-CD34-FITC (BD), or anti-CD34-APC and anti-CD38-PE Abs (BD). Cell surface expression of MT1-MMP or RECK on human CD45 + or CD34 + cells was assessed by rabbit anti-human MT1-MMP Abs (Chemicon) or mouse anti-human RECK Abs (MBL International Corp.), respectively, followed by secondary PE-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) or Alexa Fluor 488-conjugated donkey anti-mouse IgG (Invitrogen), and analyzed by FACSCalibur (BD). The percentage of immature CD34 + cells in the leukapheresis products of the patients was evaluated as described above using anti-CD45-FITC and anti-CD34-PE Abs. Cell surface expression of MT1-MMP on progenitor cells in the apheresis collections was determined by cell labeling with anti-MT1-MMP Abs (Chemicon), anti-CD34-FITC (BD), and anti-CD45-PC5 (Beckman Coulter) and analyzed by Coulter XL (Beckman Coulter). Membranal CD44 expression on human cells in the BM and PB of chimeric mice was determined by flow cytometry following colabeling with anti-CD44-PE Abs (eBioscience) or anti-human CD44 (Serotec), followed by secondary PE-conjugated Abs and anti-human specific CD45-FITC (IQ Corporation) and anti-CD34-APC (BD) Abs. Intracellular staining with anti-phospho-Akt (Thr308) Abs (Cell Signaling Technology Inc.), following fixation and permeabilization of BM cells from chimeric mice, was performed according to the manufacturer's instructions.
Mice and homing experiments. All mouse experiments were approved by the Animal Care and Use Committee of the Weizmann Institute of Science. NOD/SCID and B6.SJL mice were bred and maintained under defined flora conditions at the Weizmann Institute of Science. Balb/c mice were purchased from Harlan. CD44 KO mice and their genotyping by PCR have been previously described (45) . For the homing experiments with human progenitor cells, CD34 + cells were enriched from the PB of G-CSF-treated donors and either incubated for 30 min with 50 μg/ml of the Abs indicated in Figure 5A and Results or transfected with a siRNA as described below. Twelve to sixteen hours after transplantation of 0.5-1 × 10 6 CD34 + cells into sub-lethally irradiated NOD/SCID mice, the presence of human CD34 + and CD45 + cells in the BM was analyzed by flow cytometry as previously described (13) . MT1-MMP-deficient mice were provided by Motoharu Seiki (Institute of Medical Science, University of Tokyo, Tokyo, Japan) (47) . BM mononuclear cells were isolated from 12-to 14-day-old MT1-MMP KO and WT littermates labeled with 10 μM CFSE (Invitrogen) and injected i.v. at different cell doses (1-7.5 × 10 6 cells) into sub-lethally irradiated NOD/SCID mice. Three hours after transplantation, cells were detected in the BM by flow cytometry.
G-CSF mobilization experiments. Balb/c mice were treated with 5 daily s.c. injections of 300 μg/kg rhG-CSF and, where indicated in the figure legends, 480 μg/kg rapamycin (sirolimus, brand name Rapamune; Wyeth Europa Ltd.). Colony formation assay in cytokine-supplemented semi-solid medium of mouse PB progenitors and analysis of murine lineage -c-kit + Sca-1 + primitive cell population by flow cytometry was performed as previously described (4) . The number of colonies per milliliter of blood was calculated based on number of ficolled mononuclear cells obtained from 0.7 ml blood. Engraftment and mobilization experiments in NOD/SCID mice were performed as previously described (48) . Where indicated, 20 μg rabbit anti-human MT1-MMP (Chemicon), mouse anti-human RECK (MBL International Corp.), non-immune mouse anti-human IgG (Serotec Ltd.), or rabbit anti-human VLA-6 (Santa Cruz Biotechnology Inc.) were injected i.p. into each mouse. Following cardiac aspiration of PB from euthanized mice and BM flushing from 4 or 6 bones, the presence of human cells in the recipient NOD/SCID mice was detected with human-specific anti-CD45-APC (IQ Corporation), anti-CD34-FITC (BD), and anti-CD38-PE Abs (BD) and analyzed by FACSCalibur (BD). Mice showing greater than 15% human cell engraftment (average engraftment levels were greater than 50%) in the BM were used for further experiments. The number of human cells/ml PB was calculated as follows: (percentage of human cells in PB) × (total white blood cell number/ml) × (percentage of human cells in BM relative to control). To examine MT1-MMP and RECK expression on gated human CD34 + progenitors by flow cytometry, mononuclear cells from the BM of untreated chimeric mice were cultured for 48 hours in the presence or absence of 100 ng/ml rhG-CSF and either 10-20 μM LY294002 (Calbiochem) or equal volume of DMSO vehicle.
B6.SJL (CD45.1 + ) mice were sub-lethally irradiated (600 cGy) and transplanted 4 hours later with total BM cells from MT1-MMP KO or WT CD45.2 + donors. After 5 weeks, mice were subjected to 3 daily s.c. injections of 300 μg/kg rhG-CSF or PBS and sacrificed 6-8 hours after the last injection. BM engraftment and G-CSF-induced mobilization of donor cells were analyzed by flow cytometry using anti-mouse CD45.2-PE and c-kit-APC Abs (eBioscience).
Real-time quantitative PCR. RNA isolation and cDNA synthesis were performed as previously described (49) . Real-time PCR was done using ABI 7000 machine with SYBR Green PCR Master Mix (Applied Biosystems). Human-specific primers were as follows: MT1-MMP, sense, 5′-CATGGGCAGCGATGAAGTCT-3′, antisense, 5′-CCAGTATTT-GTTCCCCTTGTAGAAGTA-3′; for RECK, sense, 5′-GAAATGGGCTCG-GTTTGTTG-3′, antisense, 5′-TTCTCGGCAGTTTGTGTGATG-3′; for GAPDH, sense, 5′-AGCCTCAAGATCATCAGCAATG-3′, antisense, 5′-CACGATACCAAAGTTGTCATGGAT-3′. Mouse-specific primers were as follows: for MT1-MMP, sense, 5′-ACATCTGTGACGGGAACTTTGA-3′,
Figure 8
Proposed mechanism of MT1-MMP-mediated HPC mobilization. In the absence of mobilizing stimuli (e.g., G-CSF), proteolytic activities of MT1-MMP, MMP-2, and MMP-9 are relatively low due to inhibition by RECK. Functional membranal CD44 contributes to progenitor cell adhesion to the BM components (retention). G-CSF signaling induces PI3K-mediated Akt phosphorylation, increasing MT1-MMP and decreasing RECK expression. The opposed changes in MT1-MMP and RECK levels result in MT1-MMP-mediated CD44 proteolysis as well as MMP-2 and MMP-9 secretion and activation. Collectively, these changes reduce progenitor cell retention and facilitate their egress and mobilization.
